Estimating the Cost of Nosocomial Candidemia in the United States
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Sir—Candida species are the fourth most common cause of bloodstream infections in the United States [1] and are associated with an attributable mortality of up to 38% [2]. Recent estimates published in this journal suggest that each case of nosocomial candidemia results in excess costs of $34,123 per Medicare patient and $44,536 per private insurance patient, with national costs of nosocomial candidemia exceeding $200 million per year in the United States [3]. However, since that report was generated, our understanding of the epidemiology of nosocomial candidemia has significantly improved. In the recent report estimating national costs of nosocomial candidemia, an incident case of candidemia was identified through International Classification of Diseases, 9th revision (ICD-9), discharge diagnoses listed in the Nationwide Inpatient Sample (NIS) database [3]. Until that time, this method was the best mechanism for estimation of incidence, since population-based estimates of candidemia were lacking. One limitation of ICD-9 codes is that they have been developed for billing purposes, and billing personnel typically use no more than 15 ICD-9 codes for a given hospitalization. Other investigators have found that identifying incident cases of infection by this method can result in underestimation [4]. Potential for underestimation may be especially pertinent when patients generate numerous diagnoses during a complicated hospitalization, as is the case with many patients with nosocomially acquired candidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall attributable costs are difficult to calculate with precision, but have been estimated to be close to 1 billion dollars in the United States annually.21”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [21]
In the citing paper
“however, it should be noted that persistent fungemia with C. parapsilosis has been observed in the face of caspofungin therapy (163).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [163]
Citations
Cites
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Self-citationThe Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310
Guevara, R. E., Butler, J. C., Marston, B. J., Plouffe, J. F., File, T. M., & Breiman, R. F. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009804 · Cited by 140
Acalculous Cholecystitis Associated withPlasmodium falciparumInfection
Dylewski, J. S., & Al‐Azragi, T. (1999) · Clinical Infectious Diseases · doi:10.1086/520474 · Cited by 20
Acalculous Cholecystitis Associated with Plasmodium falciparum Malaria
Sanchez, R., Portilla, J., Boix, V., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/313944 · Cited by 18
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
“(159) suggested that excess medical costs incurred as a result of”
BackgroundGarey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
“Given the prevalence of Candida infections and their attributable impact on mortality and LOS, it is not surprising that these infections are associated with substantial health care costs (Fridkin 2005; Miller et al. 2001a; Pelz et al. 2000; Perlroth et al. 2007; Rentz et al. 1998; Wilson et al. 2002).”
BackgroundInfluentialThe distinct morphogenic states of Candida albicans
Sudbery, P., Gow, N., & Berman, J. (2004) · Trends in Microbiology · doi:10.1016/j.tim.2004.05.008 · Cited by 876
Candida albicans: A molecular revolution built on lessons from budding yeast
Berman, J., & Sudbery, P. E. (2002) · Nature Reviews Genetics · doi:10.1038/nrg948 · Cited by 578
“albicans is the fourth most common hospital-acquired infection in the United States, the treatment of which is estimated to cost more than US d1 billion annuall”
BackgroundRegulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
“Species of Candida are the fourth most common cause of hospital-acquired infectious diseases in the United States, costing the health care system an estimated $1 billion annually (120, 382).”
BackgroundDiazGranados, C. A., Zimmer, S. M., Mitchel, K., & Jernigan, J. A. (2005) · Clinical Infectious Diseases · doi:10.1086/430909 · Cited by 459
Invasive Fungal Pathogens: Current Epidemiological Trends
Pfaller, M. A., Pappas, P. G., & Wingard, J. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504490 · Cited by 448
“billion dollars per year [9, 11, 41-43].”
Antifungal Chemical Compounds Identified Using a C. elegans Pathogenicity Assay
Breger, J., Fuchs, B. B., Aperis, G., Moy, T. I., Ausubel, F. M., & Mylonakis, E. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030018 · Cited by 332
“$1 billion per year and the average cost of candidemia for a single episode is about $40,000 (1997 United States dollar) [5,6].”
BackgroundPfaller, M. A., Diekema, D. J., & Sheehan, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.435-447.2006 · Cited by 295
“Although much of this cost can be attributed to length of stay in hospital, the cost of antifungal therapy, especially the newer lipid formulations of amphotericin B, the echinocandins, and the extended-spectrum triazoles, is not inconsequential (41, 46, 60, 111).”
BackgroundKadosh, D., & Johnson, A. D. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-01-0073 · Cited by 289
“Currently, approximately $1 billion per year is spent on the treatment of patients with hospitalacquired infections in the United States alone (Miller et al., 2001).”
BackgroundRecent insights into Candida albicans biofilm resistance mechanisms
Mathé, L., & Van Dijck, P. (2013) · Current Genetics · doi:10.1007/s00294-013-0400-3 · Cited by 271
“…rates varying from 30 to 70 % (Bouza et al. 2013; Falagas et al. 2006; Kibbler et al. 2003; Peng and Lu 2013; Wey et al. 1988; Wisplinghoff et al. 2004) and high healthcare costs with estimates ranging from millions to 1 billion dollars in the US alone (Miller et al. 2001; Wilson et al. 2002).”
Invasive candidiasis in the intensive care unit
Ostrosky-Zeichner, L., & Pappas, P. G. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000201897.78123.44 · Cited by 247
UME6 , a Novel Filament-specific Regulator of Candida albicans Hyphal Extension and Virulence
Banerjee, M., Thompson, D. S., Lazzell, A., Carlisle, P. L., Pierce, C., Monteagudo, C., López-Ribot, J. L., & Kadosh, D. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-11-1110 · Cited by 243
“In this country approximately $1 billion per year is spent on antifungal treatments for patients with hospital-acquired Candida infections (Miller et al., 2001).”
BackgroundCX3CR1-dependent renal macrophage survival promotes Candida control and host survival
Lionakis, M. S., Swamydas, M., Fischer, B. G., Plantinga, T. S., Johnson, M. D., Jaeger, M., Green, N. M., Masedunskas, A., Weigert, R., Mikelis, C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci71307 · Cited by 230
“Analysis of fractalkine receptor CX(3) CR1 function by targeted deletion and green fluorescent protein reporter gene insertion.”
Sun, L., Liao, K., & Wang, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117695 · Cited by 166
“The estimated annual cost of treating Candida infection exceeds $1 billion [1,2].”
BackgroundDumitru, R., Hornby, J. M., & Nickerson, K. W. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2350-2354.2004 · Cited by 143
“The annual cost of treating candidal infections in the United States has been estimated at 1 billion dollars (22).”
BackgroundPitarch, A., Jiménez, A., Nombela, C., & Gil, C. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500243-mcp200 · Cited by 141
“Not only does systemic candidiasis (SC)(1) continue to be significant in incidence (1–3), but it also remains a leading infectious cause of morbidity and mortality in intensive care, post-surgical, and cancer patients (3–5) and accounts for substantial healthcare costs (6, 7).”
BackgroundInvasive candidiasis in immunocompromised hospitalized patients.
Sims, C. R., Ostrosky-Zeichner, L., & Rex, J. H. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.05.015 · Cited by 124
Changing Strategies for the Management of Invasive Fungal Infections
Rapp, R. P. (2004) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.3.4s.33151 · Cited by 125
“Clearly, treatment options with improved efficacy, safety, and tolerability would lower the cost of the illness.(59) Treatment of systemic fungal infections with conventional amphotericin B is frequently complicated by severe nephrotoxicity that is often dose limiting and irreversible, and prolongs hospital stay with…”
BackgroundLionakis, M. S., Fischer, B. G., Lim, J. K., Swamydas, M., Wan, W., Richard Lee, C.-C., Cohen, J. I., Scheinberg, P., Gao, J.-L., & Murphy, P. M. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002865 · Cited by 118
“annual cost of two billion dollars in the US [1–3].”
BackgroundFazly, A., Jain, C., Dehner, A. C., Issi, L., Lilly, E. A., Ali, A., Cao, H., Fidel, P. L., P. Rao, R., & Kaufman, P. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305982110 · Cited by 112
“The piperzinyl quinolone Q1 was described (1) as a compound that reverses fluconazole resistance.”
BackgroundMethodInfluentialNew insights into innate immune control of systemic candidiasis
Lionakis, M. S. (2014) · Medical Mycology · doi:10.1093/mmy/myu029 · Cited by 109
“It is now estimated that more than 50 000 new cases of systemic candidiasis occur in the United States every year (incidence, approximately 20 cases/10 000 population), with an associated annual cost of more than $2 billion [1–4].”
BackgroundOkoli, I., Coleman, J. J., Tempakakis, E., An, W. F., Holson, E., Wagner, F., Conery, A. L., Larkins-Ford, J., Wu, G., Stern, A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007025 · Cited by 106
“The overall excess cost attributable to candidemia is estimated at $1 billion per year [43], while the average cost of treating a single episode of candidemia is $34,123–44,536 (1997”
BackgroundNavarathna, D. H. M. L. P., Hornby, J. M., Hoerrmann, N., Parkhurst, A. M., Duhamel, G. E., & Nickerson, K. W. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki383 · Cited by 88
Jaeger, M., van der Lee, R., Cheng, S.-C., Johnson, M. D., Kumar, V., Ng, A., Plantinga, T. S., Smeekens, S. P., Oosting, M., Wang, X., et al. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2309-2 · Cited by 86
Slenker, A. K., Keith, S. W., & Horn, D. L. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.02.004 · Cited by 91
“6% to 57% (Pappas et al., 2003; Gudlaugsson et al., 2003; Morgan et al., 2005; Miller et al., 2001; National Nosocomial Infections Surveillance, 1999; Rentz et al., 1998; Wey et al., 1988; Zaoutis et al., 2005).”
BackgroundInfluentialSwamydas, M., Gao, J.-L., Break, T. J., Johnson, M. D., Jaeger, M., Rodriguez, C. A., Lim, J. K., Green, N. M., Collar, A. L., Fischer, B. G., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7718 · Cited by 79
“Systemic candidiasis, most often caused by the commensal yeast Candida albicans, has emerged as the leading cause of nosocomial bloodstream infection in acutely ill and immunocompromised patient populations in the United States (1), with an estimated annual cost that exceeds 2 billion dollars (2, 3).”
BackgroundManoharan, R. K., Lee, J.-H., Kim, Y.-G., Kim, S.-I., & Lee, J. (2017) · Biofouling · doi:10.1080/08927014.2017.1280731 · Cited by 78
“Candida albicans is a yeast pathogen known for its virulence and high morbidity rate (Miller et al. 2001; Pappas et al. 2003).”
BackgroundCarlisle, P. L., & Kadosh, D. (2010) · Eukaryotic Cell · doi:10.1128/ec.00046-10 · Cited by 70
“Currently, the United States spends approximately $1 billion per year for antifungal therapies to treat systemic candidiasis (19).”
BackgroundSpellberg, B., Johnston, D., Phan, Q. T., Edwards, J. E., French, S. W., Ibrahim, A. S., & Filler, S. G. (2003) · Infection and Immunity · doi:10.1128/iai.71.10.5756-5764.2003 · Cited by 68
“Candida is the fourth most common bloodstream isolate in the nosocomial setting (31), and the cost associated with nosocomial candidemia in the United States approaches one billion dollars per year (18).”
BackgroundSelf-citationGarey, K. W., Pai, M. P., Suda, K. J., Turpin, R. S., Rege, M. D., Mingo, D. E., & Bearden, D. T. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1365 · Cited by 64
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62
Kasai, M., Francesconi, A., Petraitiene, R., Petraitis, V., Kelaher, A. M., Kim, H.-S., Meletiadis, J., Sein, T., Bacher, J., & Walsh, T. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.1.143-150.2006 · Cited by 60
“Invasive candidiasis remains one of the leading causes of morbidity and mortality in immunocompromised and critically ill patients (1, 8, 9, 15, 18, 20, 23), with Candida albicans infections comprising 45% of all Candida bloodstream infections (10).”
BackgroundDevelopments in the treatment of candidiasis: more choices and new challenges
Aperis, G., Myriounis, N., Spanakis, E. K., & Mylonakis, E. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.11.1319 · Cited by 56
“In the USA, the cost attributable to candidaemia is approaching US$1 billion/year and a cost of illness analysis estimated the average cost of candidaemia for a single episode of care in 1997 to be US$34,123/Medicare patient and US$44,536/private insurance patient [11,12].”
BackgroundA Re-Evaluation of the Relationship between Morphology and Pathogenicity in Candida Species
Kadosh, D., & Mundodi, V. (2020) · Journal of Fungi · doi:10.3390/jof6010013 · Cited by 70
“alone, approximately $1 billion per year is spent on the treatment of patients with hospital-acquired Candida infections [11].”
BackgroundCandidainfection and colonization among non-trauma emergency surgery patients
Kourkoumpetis, T. K., Manolakaki, D., Velmahos, G. C., Chang, Y., Alam, H. B., Moya, M. M. D., Sailhamer, E. A., & Mylonakis, E. E. (2010) · Virulence · doi:10.4161/viru.1.5.12795 · Cited by 70
Sensing the host environment: recognition of hemoglobin by the pathogenic yeast Candida albicans
Pendrak, M. L., Yan, S. S., & Roberts, D. D. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.02.006 · Cited by 55
Histidine kinases keep fungi safe and vigorous
Li, D., Agrellos, O. A., & Calderone, R. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.04.007 · Cited by 58
The role of Candida albicans AP-1 protein against host derived ROS in in vivo models of infection
Jain, C., Pastor, K., Gonzalez, A. Y., Lorenz, M. C., & Rao, R. P. (2013) · Virulence · doi:10.4161/viru.22700 · Cited by 45
Childers, D. S., Mundodi, V., Banerjee, M., & Kadosh, D. (2014) · Molecular Microbiology · doi:10.1111/mmi.12576 · Cited by 49
“, 2004) and approximately $1 billion per year is spent in this country on antifungal therapies to treat systemic candidiasis (Miller et al., 2001).”
BackgroundAntifungal Drug Discovery through the Study of Invertebrate Model Hosts
Pukkila-Worley, R., Holson, E. B., Wagner, F. F., & Mylonakis, E. E. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788186237 · Cited by 49
Progress and prospects for targeting Hsp90 to treat fungal infections
VERI, A., & COWEN, L. E. (2014) · Parasitology · doi:10.1017/s0031182013002072 · Cited by 43
“Hsp90’s impact on drug resistance has been studied most extensively in Candida species, which are the fourth most frequent cause of hospitalacquired infections, imposing an economic burden on the healthcare system of over $1 billion annually in the USA alone (Miller et al. 2001).”
BackgroundControl of Candida albicans morphology and pathogenicity by post-transcriptional mechanisms
Kadosh, D. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2294-y · Cited by 48
Cell Surface Hydrophobicity as a Virulence Factor in Candida albicans
Goswami, R. R., Pohare, S. D., Raut, J. S., & Karuppayil, S. M. (2017) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/2598 · Cited by 38
UsingCaenorhabditis elegansfor antimicrobial drug discovery
Desalermos, A. P., Muhammed, M., Glavis‐Bloom, J., & Mylonakis, E. E. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.573781 · Cited by 46
“The cost of infections reaches $1 billion/year and the average cost of dealing with a case of systemic candidiasis in 1997 was estimated at $34,123 -- 44,536 [13,14].”
BackgroundSolasodine-3-O-β-d-glucopyranoside kills Candida albicans by disrupting the intracellular vacuole
Chang, W., Li, Y., Zhang, M., Zheng, S., Li, Y., & Lou, H. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.05.045 · Cited by 38
SSD1 Is Integral to Host Defense Peptide Resistance in Candida albicans
Gank, K. D., Yeaman, M. R., Kojima, S., Yount, N. Y., Park, H., Edwards, J. E., Filler, S. G., & Fu, Y. (2008) · Eukaryotic Cell · doi:10.1128/ec.00402-07 · Cited by 37
“Thus, understanding the relationship among candidal pathogenicity, molecular immunobiology, and host defense is directly relevant to addressing the unacceptably high rates of morbidity and mortality presently associated with candidal infection (1, 12, 23, 27).”
BackgroundSelf-citationDoyle, T. C., Nawotka, K. A., Purchio, A. F., Akin, A. R., Francis, K. P., & Contag, P. R. (2006) · Microbial Pathogenesis · doi:10.1016/j.micpath.2005.11.002 · Cited by 38
Identification of airborne microbiota in selected areas in a health-care setting in South Africa
Lenetha, G. G., Malebo, N. J., Shale, K., & Lues, R. J. F. (2014) · BMC Microbiology · doi:10.1186/1471-2180-14-100 · Cited by 35
The Epidemiology of Invasive Candidiasis
Pfaller, M. A., & Diekema, D. J. (2014) · Candida and Candidiasis · doi:10.1128/9781555817176.ch29 · Cited by 33
Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance® registry
Neofytos, D., Huprikar, S. S., Reboli, A. C., Schuster, M. G., Azie, N. E., Franks, B., & Horn, D. (2013) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-1939-0 · Cited by 34
“The crude mortality rates for patients with Candida osteomyelitis appear to be lower than those for other forms of invasive candidiasis, such as candidemia, where the crude mortality rates are generally much higher (31–57 %) [2, 12–20].”
BackgroundMultidrug-Resistant Transporter Mdr1p-Mediated Uptake of a Novel Antifungal Compound
Sun, N., Li, D., Fonzi, W., Li, X., Zhang, L., & Calderone, R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01504-13 · Cited by 30
Population dynamics and the evolution of antifungal drug resistance in Candida albicans
Huang, M., & Kao, K. C. (2012) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2012.02587.x · Cited by 36
“In the United States, the treatment associated with Candidemia cost more than US $1 billion annually (Beck-Sague & Jarvis, 1993; Miller et al., 2001).”
BackgroundXie, C., Sun, L., Meng, L., Wang, M., Xu, J., Bartlam, M. G., & Guo, Y. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.09.013 · Cited by 28
Milestones in Candida albicans gene manipulation
Samaranayake, D. P., & Hanes, S. D. (2011) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2011.04.003 · Cited by 29
“Today, candidemia is one of the leading bloodstream infections in the United States with an annual cost of treatment approaching $1 billion (Miller et al., 2001).”
BackgroundAlex, D., Gay‐Andrieu, F., May, J. P., Thampi, L. M., Dou, D., Mooney, A., Groutas, W. C., & Calderone, R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00477-12 · Cited by 28
Global translational landscape of the Candida albicans morphological transition
Mundodi, V., Choudhary, S., Smith, A. D., & Kadosh, D. (2020) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkaa043 · Cited by 24
Pammi, M., Eddama, O., & Weisman, L. E. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006068.pub3 · Cited by 26
Song, S., Sun, X., Meng, L., Wu, Q., Wang, K., & Deng, Y. (2020) · Microbial Biotechnology · doi:10.1111/1751-7915.13601 · Cited by 28
“It is estimated that the annual cost of treating Candida infections is more than $1 billion (Miller et al., 2001; Pappas et al., 2003).”
BackgroundPharmacoeconomics of antifungal pharmacotherapy – challenges and future directions
Johnson, M. D., Kleinberg, M. E., Danziger, L. H., & Ostrosky-Zeichner, L. L. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.15.2617 · Cited by 25
“With increased frequency of candidaemia and more expensive antifungal therapies, the impact on the healthcare system from managing cases of candidaemia has been estimated to be much greater than estimated in this particular study – probably almost $1 billion per year [28].”
BackgroundGenomics and the development of new diagnostics and anti-Candida drugs
Weig, M., & Brown, A. J. P. (2007) · Trends in Microbiology · doi:10.1016/j.tim.2007.05.007 · Cited by 29
Candidaemia in the non-neutropenic patient: A critique of the guidelines
Deshpande, A., Gaur, S., & Bal, A. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.06.005 · Cited by 26
Kadosh, D., Najvar, L. K., Bocanegra, R. A., Olivo, M., Kirkpatrick, W. R., Wiederhold, N. P., & Patterson, T. F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01144-16 · Cited by 20
“Approximately $1 billion is spent annually on the treatment of patients with hospital-acquired Candida infections in the United States alone (9).”
BackgroundNon-steroidal anti-inflammatory drugs may modulate the protease activity of Candida albicans
Carvalho, A. P., Gursky, L. C., Rosa, R. T., Rymovicz, A. U. M., Campelo, P. M. S., Grégio, A. M. T., Koga‐Ito, C. Y., Samaranayake, L. P., & Rosa, E. A. R. (2010) · Microbial Pathogenesis · doi:10.1016/j.micpath.2010.07.007 · Cited by 22
Wells, M. L., Washington, O. L., Hicks, S. N., Nobile, C. J., Hartooni, N., Wilson, G. M., Zucconi, B. E., Huang, W., Li, L., Fargo, D. C., et al. (2015) · Molecular Microbiology · doi:10.1111/mmi.12913 · Cited by 20
“albicans is the fourth most common cause of hospitalacquired infectious diseases in the United States (Miller et al., 2001).”
BackgroundJohnson, C. M., O’Brien, X. M., Byrd, A. S., Parisi, V., Loosely, A. J., Li, W., Witt, H. A., Faridi, H. M., Lefort, C. T., Gupta, V., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502381 · Cited by 22
Antifungal activities of Equol against Candida albicans in vitro and in vivo
Wang, F., Zhang, J., Zhang, Q., Song, Z., & Xin, C. (2024) · Virulence · doi:10.1080/21505594.2024.2404256 · Cited by 18
“The cost of treating candida infection was 1.4 billion annually in the US alone in 2019 [32–34].”
BackgroundInfluentialEdwards, J. E. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00257-5 · Cited by 19
Self-citationGrau, S., Salavert, M., Laderas, J. C. P., Vargas, M., Barrueta, J. A., & Mir, N. (2013) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2013.05.004 · Cited by 15
Whole animal HTS of small molecules for antifungal compounds
Muhammed, M., Arvanitis, M., & Mylonakis, E. E. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1122591 · Cited by 14
Agwan, V., Butola, R., & Madan, M. (2015) · Indian Journal of Pathology and Microbiology · doi:10.4103/0377-4929.168873 · Cited by 15
Zhao, S., Huang, J., Sun, X., Huang, X., Fu, S., Yang, L., Liu, X., He, F., & Deng, Y. (2018) · Microbial Biotechnology · doi:10.1111/1751-7915.13307 · Cited by 13
“It can also induce life-threatening systemic infections known as candidemia in immunocompromised patients (Miller et al., 2001; Pappas et al., 2003).”
BackgroundFunctional Genomics Approaches for the Identification and Validation of Antifungal Drug Targets
Backer, M. D. D., Dijck, P. V., & Luyten, W. H. M. L. (2002) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200202020-00004 · Cited by 13
Nunes, E. B., Nunes, N. B., Monteiro, J. C. M. S., & Paes, A. L. V. (2011) · Revista Pan-Amazônica de Saúde · doi:10.5123/s2176-62232011000400004 · Cited by 23
Utility of Insects for Studying Human Pathogens and Evaluating New Antimicrobial Agents
Wang, Y., Li, D., Jiang, Y., & Mylonakis, E. E. (2013) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2013_194 · Cited by 13
New developments in the antifungal susceptibility testing of Candida
Pfaller, M. A. (2008) · Current Fungal Infection Reports · doi:10.1007/s12281-008-0019-x · Cited by 10
Singh, S., Youssef, E. G., Barbarino, A. M., Hautau, H., Nabeela, S., Gebremariam, T., Alkhazraji, S., Ostroff, G. R., Christensen, D., Cochrane, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-32488-8 · Cited by 10
Pammi, M., Eddama, O., & Weisman, L. E. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006068.pub2 · Cited by 11
Flow cytometry-based method to detect persisters in Candida albicans
Chang, W., Zhang, M., Li, Y., & Lou, H. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00255-15 · Cited by 7
“albicans-caused infection is most frequently associated with biofilm formation in immunocompromised patients (3).”
BackgroundMundodi, V., Choudhary, S., Smith, A. D., & Kadosh, D. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02195-24 · Cited by 8
“of hospital-acquired Candida infections (9, 10).”
Genome-wide translational response of Candida albicans to fluconazole treatment
Choudhary, S., Mundodi, V., Smith, A. D., & Kadosh, D. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02572-23 · Cited by 8
“The cost of treating patients with hospital-acquired Candida infections is approximately $1 billion per year (9, 10).”
BackgroundNikolić, D. (2014) · British Journal of Biomedical Science · doi:10.1080/09674845.2014.11669968 · Cited by 9
Okoli, I. G., Coleman, J. J., Tampakakis, E., An, W. F., Holson, E. B., Wagner, F. F., Conery, A. L., Larkins‐Ford, J., Wu, G., Stern, A., et al. (2010) · PLoS ONE · doi:10.1371/annotation/76699885-a47e-426c-accd-35576696c4f2 · Cited by 7
Reitler, P., Regan, J., DeJarnette, C. A., Srivastava, A., Carnahan, J., Tucker, K. M., Meibohm, B., Peters, B. M., & Palmer, G. E. (2024) · Infection and Immunity · doi:10.1128/iai.00072-24 · Cited by 8
Yoğun bakım ünitesinde bakteriyemi tanısı ile takip edilen hastaların değerlendirilmesi
Akyıldız, Ö., Besli, Y., & Kocagöz, A. S. (2019) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.623795 · Cited by 8
Lu, L., Li, Z., Shan, C., Ma, S., Nie, W., Wang, H., Chen, G., Li, S., & Shu, C. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.04.019 · Cited by 7
Novel approaches to antifungal prophylaxis
Ostrosky-Zeichner, L. L. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.6.665 · Cited by 5
“Invasive aspergillosis has a reported mortality as high as 90% and invasive candidiasis has an attributable mortality of 30%, with estimated costs as high as $40,000 per episode [12-19].”
BackgroundSierra, B. H., Palomino, M. Á. P., Balsera, E. C., Bono, J. M., García, G. Q., & Arias-Verdú, M. D. (2009) · Medicina Intensiva · doi:10.1016/s0210-5691(09)70948-9 · Cited by 6
“La mediana de estancia en la unidad fue 14 (11-18) días y en el 53,8% de los casos la candidiasis se diagnosticó precozmente, la primera semana del ingreso.”
BackgroundKurtoğlu, M., Bozkurt, H. B., Tuncer, O., Keşli, R., & Berktaş, M. (2008) · Journal of International Medical Research · doi:10.1177/147323000803600613 · Cited by 5
An Investigation of the Potential Antifungal Properties of CNC-2 in Caenorhabditis elegans.
Zehrbach, A. M. D., Rogers, A. R., & Tarr, D. E. K. (2017) · PubMed · Cited by 4
Prabhakaran, N., Umamageswaria, S. S. M., Muthumari, M., & Mohan, K. (2016) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.10.4.94 · Cited by 3
Nikolić, D. (2017) · Vojnosanitetski pregled · doi:10.2298/vsp151216028n · Cited by 6
Sims, C. R., & Ostrosky-Zeichner, L. L. (2008) · Elsevier eBooks · doi:10.1016/b978-141603158-1.10015-0 · Cited by 2
Insights in Antifungal Drug Discovery
Gay‐Andrieu, F., May, J. P., Li, D., Sun, N., Chen, H., Calderone, R., & Alex, D. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch24 · Cited by 2
Pammi, M., Asim, O., & Weisman, L. E. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006068 · Cited by 2
Palomino, M. Á. P., Sierra, B. H., Bono, J. M., Balsera, E. C., Mora-Ordóñez, J. M., & Verdú, L. A. (2008) · MEDICRIT Revista de Medicina Crítica · doi:10.5413/mrmc.2008.51.91 · Cited by 1
Ellsworth, M., Sims, C. R., & Ostrosky-Zeichner, L. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2662-6.00017-1 · Cited by 1
Cell individuality in adhesin expression of Candida glabrata
Halliwell, S. (2012) · Nottingham ePrints (University of Nottingham) · Cited by 1
Caracterização das bases moleculares da suscetibilidade imunológica à infecção por Candida albicans
Agustinho, D. P. (2015) · RIUnB Institutional Repository (University of Brasília) · doi:10.26512/2015.02.t.18734
Metadata
- Authors
- Miller, L. G., Hajjeh, R. A., & Edwards, J. E.
- Affiliations
- University of California, Los Angeles (US)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Miller, L. G.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-04-01
- Volume
- 32
- Issue
- 7
- Pages
- 1110-1110
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2153953877
- Cited by
- 109
- References
- 7
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 1 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 7 · 2016: 7 · 2015: 7 · 2014: 9 · 2013: 10 · 2012: 6
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
- Keywords
- nosocomial candidemia, candidemia, health care costs, cost estimation, National Inpatient Sample, incidence estimation, Medicare, private insurance, hospitalization
- MeSH terms
- Candidiasis, Humans, United States, Fungemia, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.